ASH: Survival benefit of Daiichi Sankyo's FLT3 inhibitor quizartinib
Japanese pharma major Daiichi Sankyo (TYO: 4568) yesterday announced positive comprehensive analyses of overall survival from the pivotal QuANTUM-R Phase III study of single agent quizartinib compared to salvage chemotherapy in patients with FLT3-ITD acute myeloid leukemia (AML), which was refractory or relapsed within six months of first remission, at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego.
The company’s shares closed the day up 2.98% at 4,291 yen.
Pre-specified sensitivity analyses of overall survival and event-free survival as well as predefined subgroup analyses from the QuANTUM-R study of quizartinib were found to be consistent with the primary analysis of overall survival. Analyses of key exploratory endpoints such as composite complete remission (CRc), duration of CRc and hematopoietic stem cell transplant (HSCT) rate also were consistent with, and supportive of, the primary overall survival benefit demonstrated in QuANTUM-R.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze